Abbott Laboratories

Abbott Laboratories

ABT·NYSE

$87.02

-0.82%
HealthcareMedical - Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

At a Glance

Live Snapshot
Market Cap$151.57B
EPS3.7400
P/E Ratio23.27
Earnings Date07/16/2026
8.43%
Return on Invested Capital
-15%
3Y-26.0%
5Y+8.0%
10Y+71.0%
12.51%
Return on Equity
-55%
3Y-34.0%
5Y-9.0%
10Y+84.0%
7.52%
Return on Assets
-54%
3Y-19.0%
5Y+21.0%
10Y+196.0%
Abbott Laboratories

Abbott Laboratories Management Team

ABT · NYSE
MR

Mr. Robert B. Ford

Chairman of the Board, President & Chief Executive Officer

Compensation

$4,980,248

Born 1974(Age 52)
male
MP

Mr. Philip P. Boudreau

Chief Financial Officer & Executive Vice President of Finance

Compensation

$2,183,487

Born 1973(Age 53)
male
ML

Ms. Lisa D. Earnhardt

Executive Vice President & Group President of Medical Devices

Compensation

$2,258,516

Born 1970(Age 56)
female
MD

Mr. Daniel Gesua Sive Salvadori

Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products

Compensation

$1,891,684

Born 1979(Age 47)
male
MM

Ms. Mary K. Moreland

Executive Vice President of Human Resources

Born 1966(Age 60)
female
MH

Mr. Hubert L. Allen J.D.

Executive Vice President, General Counsel & Secretary

Compensation

$2,546,024

Born 1966(Age 60)
male
ME

Ms. Elizabeth Cushman

Executive Vice President, General Counsel & Secretary

female
MS

Ms. Sabina Ewing

Senior Vice President of Business & Technology Services and Chief Information Officer

Born 1974(Age 52)
female
MM

Ms. Melissa Brotz

Senior Vice President of Global Marketing & External Affairs

female
EL

Erica L. Battaglia

Vice President and Chief Ethics & Compliance Officer

MM

Mr. Michael Comilla

Vice President of Investor Relations.

male
abt

Abbott Laboratories Insider Positioning

ABT · NYSE

During the last 12 months, insiders have purchased $3.69M and sold $1.44M worth of ABT shares, resulting in $2.25M of net buying activity.

3 Months

Bought

12.2K

1.13M

Sold

0

0.00

Net Activity

+1.1M

+$1.13M

3-6 Months

Bought

23.8K

2.56M

Sold

4.2K

485.32K

Net Activity

+2.1M

+$2.07M

6-9 Months

Bought

0

0.00

Sold

1.6K

203.04K

Net Activity

-203K

-$203K

9-12 Months

Bought

0

0.00

Sold

5.5K

746.76K

Net Activity

-747K

-$747K

Top Buyers

1
FRB

Ford Robert B

Director, Officer: Chairman And Ceo

18.8K shares1 transactions

$2.01M

2
SDJ

Starks Daniel J

Director

15.0K shares2 transactions

$1.47M

3
BPP

Boudreau Philip P

Officer: Evp And Cfo

2.2K shares1 transactions

$201K

Top Sellers

1
BPP

Boudreau Philip P

Officer: Evp And Cfo

5.5K shares1 transactions

$747K

2
SE

Shroff Eric

Officer: Senior Vice President

2.3K shares2 transactions

$285K

3
MLH

Morrone Louis H.

Officer: Executive Vice President

1.1K shares1 transactions

$132K

4
SDGS

Salvadori Daniel Gesua Sive

Officer: Evp And Group President

885 shares1 transactions

$102K

5
MMK

Moreland Mary K

Officer: Executive Vice President

613 shares1 transactions

$71K

Insider Activity Analysis

Net Insider Sentiment

Bullish

Positive insider sentiment with $2.25M net buying. Buying activity substantially exceeds selling, indicating insider confidence.

Buy/Sell Ratio

2.57:1

Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.

Recent Trend (3 Months)

$1.13M

Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.

Insider Participation

Moderate Selling

5 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.

Insider Activity Insight

Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.

SEC Filings

ABT - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2026

N/A

March 13, 2026
April 24, 2026
2026
DEF 14A

DEF 14A 2025

N/A

March 14, 2025
April 25, 2025
2025
DEF 14A

DEF 14A 2024

N/A

March 15, 2024
April 26, 2024
2024
DEF 14A

DEF 14A

N/A

March 17, 2023
March 17, 2023
 
DEF 14A

DEF 14A 2022

N/A

March 18, 2022
April 29, 2022
2022
DEF 14A

DEF 14A 2021

N/A

March 12, 2021
April 23, 2021
2021
DEF 14A

DEF 14A 2020

N/A

March 13, 2020
April 24, 2020
2020
DEF 14A

DEF 14A 2019

N/A

March 15, 2019
April 26, 2019
2019
DEF 14A

DEF 14A 2018

N/A

March 16, 2018
April 27, 2018
2018
DEF 14A

DEF 14A 2017

N/A

March 17, 2017
April 28, 2017
2017
Showing 1 to 10 of 33 filings